Rasha Aboelhassan/LinkedIn
Sep 15, 2024, 09:55
Rasha Aboelhassan: Should we try immunotherapy for all patients?
Rasha Aboelhassan shared on LinkedIn:
“Myriam Chalabi. Kok Haw Jonathan Lim. YO boxing session.
Should we try immunotherapy for all patients?
No. We should follow guidelines and it’s only dependant on patients profiles
I have another question:
Do your patient accept the long life possible side effects if he is going to have adequate survival benefit?”
Source: Rasha Aboelhassan/LinkedIn
More posts featuring Rasha Aboelhassan on oncodaily.com
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18